COVID Force

A COVID FORCE (Feasibility and Optimization of Research at Children’s) Collaborative was formed in March 2020. The mission of the COVID FORCE collaborative is to provide strategic coordination to facilitate the best possible research and remove barriers to move all research in this area forward. The collaborative has helped to provide feasibility analyses, harmonized IRB requests, coordinated sample and data utilization and sharing, helped with resource identification and allocation, and more. All investigators engaged in COVID projects or interested in submitting new projects are asked to submit their information via the REDCap COVID survey. This is for any projects conducted by Department of Pediatrics or Children's Healthcare of Atlanta researchers, and/or that will take place in Children's facilities or will involve Children's patients or data. As of June 12, 2020 this collaborative is tracking 65 COVID-related studies. If you are needing information about the studies for communications or other purposes, please contact Barbara Kilbourne or Kelcey Little


The COVID FORCE leadership team:
•Ann Chahroudi, MD, PhD
•Stacy Heilman, PhD
•Miriam B. Vos, MD, MSPH
•Rajit Basu, MD, MS, FCCM
•Evan Anderson, MD
•Evan Orenstein, MD
•Ann Mertens, PhD
•Nitika Gupta, MD


COVID Force Seminar Series


For all other non-COVID related research efforts during this time, please refer to your appropriate IRBs, sponsors, and PIs regarding individual research study recruitment, enrollment, visit changes, etc. Note that this situation is rapidly changing, and links and documents will be updated frequently. 

Emory's Department of Pediatrics intranet site has a section on Clinical Research during the COVID-19 pandemic. Note that you will need your Emory ID to login to this site.

Emory's Office of Research Administration page is regularly updated with information from sponsors and others regarding research during this time. 

Should you have any questions or difficulties accessing these pages, please reach out to Ada Chong.